A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
Condition: Salmonella Infections Interventions: Biological: Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose; Biological: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose; Biological: Typhoid conjugate vaccine (TCV) low dose; Biological: Invasive non typhoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose; Biological: Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose; Biological: Typhoid conjugate vaccine (TCV) full dose; Biological: GSK's Meningococcal A, C, Y and W-135 conjugate vaccine; Combination Product: GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine; Combination Product: Sanofi Pasteur's Typhoid Vi polysaccharide vaccine; Drug: Placebo; Other: Saline Sponsors: GlaxoSmithKline; Biomedical Advanced Research and Development Authority; Wellcome Trust Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diphtheria | Men | Meningitis | Meningitis Vaccine | Research | Salmonella | Study | Tetanus | Tetanus Diptheria Pertussis Vaccine Tdap,Dtap,Dpt | Tetanus Vaccine | Typhoid | Typhoid Vaccine | Vaccines | Whooping Cough (Pertussis) Vaccine